The purchases would increase available supply by 50 percent, bringing the total to 600 million doses by this summer.
Because both products — one developed by Pfizer and German company BioNTech and the other by Moderna — are two-dose regimens, that would be enough to fully vaccinate 300 million people. An estimated 260 million people in the United States are currently considered eligible to receive a coronavirus vaccine, though Pfizer and Moderna have initiated trials for children as young as 12, the results of which could expand the pool.
The additional supply would greatly boost President Biden’s chances of returning the nation to some semblance of normalcy by late summer or the fall. He said Monday he expects the general public to gain access to shots by the spring — as he seemed to elevate his administration’s goal from 1 million vaccinations a day to 1.5 million — though aides on Tuesday said that was aspirational.
January 26, 2021
Vaccine supply to increase slightly starting next week, White House to tell governors – The Washington Post